Neuropore Therapies, Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the underlying causes of neurodegenerative disease, announced today the appointment of Joseph S. McCracken, DVM, MS to its board of directors.
Report in Scientific Reports, describes the beneficial effects of NPT200-11 on multiple disease relevant endpoints in a transgenic mouse model of Parkinson's disease.
